Alexion Pharmaceuticals, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Alexion Pharmaceuticals, Inc. – Product Pipeline Review – 2016’, provides an overview of the Alexion Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Alexion Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Alexion Pharmaceuticals, Inc.

The report provides overview of Alexion Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Alexion Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Alexion Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Alexion Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Alexion Pharmaceuticals, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Alexion Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Alexion Pharmaceuticals, Inc. Snapshot 6

Alexion Pharmaceuticals, Inc. Overview 6

Key Information 6

Key Facts 6

Alexion Pharmaceuticals, Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

Alexion Pharmaceuticals, Inc. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Alexion Pharmaceuticals, Inc. - Pipeline Products Glance 14

Alexion Pharmaceuticals, Inc. - Late Stage Pipeline Products 14

Pre-Registration Products/Combination Treatment Modalities 14

Phase III Products/Combination Treatment Modalities 15

Alexion Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Alexion Pharmaceuticals, Inc. - Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Discovery Products/Combination Treatment Modalities 19

Alexion Pharmaceuticals, Inc. - Drug Profiles 20

sebelipase alfa 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

eculizumab 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

ALXN-1101 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

ALXN-1007 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

ALXN-1210 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Monoclonal Antibodies for Undisclosed Indication 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

SBC-103 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

ALXN-5500 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

asfotase alfa 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Drugs for Undisclosed Indications 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Drugs to Inhibit Complement System Protein 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Recombinant Enzymes for Pompe, Fabry and Hunter Diseases 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

SBC-104 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

SBC-105 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

SBC-106 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

SBC-342 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Small Molecules for Orphan Diseases 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Alexion Pharmaceuticals, Inc. - Pipeline Analysis 42

Alexion Pharmaceuticals, Inc. - Pipeline Products by Target 42

Alexion Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 43

Alexion Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 44

Alexion Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 45

Alexion Pharmaceuticals, Inc. - Recent Pipeline Updates 46

Alexion Pharmaceuticals, Inc. - Dormant Projects 69

Alexion Pharmaceuticals, Inc. - Discontinued Pipeline Products 70

Alexion Pharmaceuticals, Inc. - Discontinued Pipeline Products 70

Discontinued Pipeline Product Profiles 70

Cellular Immunotherapy for Central Nervous System 70

pexelizumab 70

Alexion Pharmaceuticals, Inc. - Company Statement 71

Alexion Pharmaceuticals, Inc. - Locations And Subsidiaries 72

Head Office 72

Other Locations & Subsidiaries 72

Appendix 76

Methodology 76

Coverage 76

Secondary Research 76

Primary Research 76

Expert Panel Validation 76

Contact Us 76

Disclaimer 77

List of Tables

List of Tables

Alexion Pharmaceuticals, Inc., Key Information 6

Alexion Pharmaceuticals, Inc., Key Facts 6

Alexion Pharmaceuticals, Inc. – Pipeline by Indication, 2016 8

Alexion Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2016 10

Alexion Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2016 11

Alexion Pharmaceuticals, Inc. – Partnered Products in Pipeline, 2016 12

Alexion Pharmaceuticals, Inc. – Partnered Products/ Combination Treatment Modalities, 2016 13

Alexion Pharmaceuticals, Inc. – Pre-Registration, 2016 14

Alexion Pharmaceuticals, Inc. – Phase III, 2016 15

Alexion Pharmaceuticals, Inc. – Phase II, 2016 16

Alexion Pharmaceuticals, Inc. – Phase I, 2016 17

Alexion Pharmaceuticals, Inc. – Preclinical, 2016 18

Alexion Pharmaceuticals, Inc. – Discovery, 2016 19

Alexion Pharmaceuticals, Inc. – Pipeline by Target, 2016 42

Alexion Pharmaceuticals, Inc. – Pipeline by Route of Administration, 2016 43

Alexion Pharmaceuticals, Inc. – Pipeline by Molecule Type, 2016 44

Alexion Pharmaceuticals, Inc. – Pipeline Products by Mechanism of Action, 2016 45

Alexion Pharmaceuticals, Inc. – Recent Pipeline Updates, 2016 46

Alexion Pharmaceuticals, Inc. – Dormant Developmental Projects,2016 69

Alexion Pharmaceuticals, Inc. – Discontinued Pipeline Products, 2016 70

Alexion Pharmaceuticals, Inc., Subsidiaries 72

List of Figures

List of Figures

Alexion Pharmaceuticals, Inc. – Pipeline by Top 10 Indication, 2016 8

Alexion Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2016 10

Alexion Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2016 11

Alexion Pharmaceuticals, Inc. – Partnered Products in Pipeline, 2016 12

Alexion Pharmaceuticals, Inc. – Pipeline by Target, 2016 42

Alexion Pharmaceuticals, Inc. – Pipeline by Route of Administration, 2016 43

Alexion Pharmaceuticals, Inc. – Pipeline by Molecule Type, 2016 44

Alexion Pharmaceuticals, Inc. – Pipeline Products by Mechanism of Action, 2016 45

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports